Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time

Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time

Source: 
Marketwatch
snippet: 

Eli Lily & Co. and Incyte Corp. said Monday that their rheumatoid arthritis drug Olumiant helped reduce recovery time in hospitalized COVID-19 patients when it was used in combination with Gilead Sciences Inc.'s remdesivir.